Tango Therapeutics (TNGX) Form 144: 302,194 Shares Proposed Sale

Tango Therapeutics, Inc. (TNGX) filed a Form 144 reporting a proposed sale of 302,194 common shares through BTIG, LLC with an aggregate market value of $2,085,138.60, intended to be sold on 08/22/2025 on the NASDAQ GM.

Rhea-AI Filing Summary

Tango Therapeutics, Inc. (TNGX) filed a Form 144 reporting a proposed sale of 302,194 common shares through BTIG, LLC with an aggregate market value of $2,085,138.60, intended to be sold on 08/22/2025 on the NASDAQ GM. The filer acquired these shares on 03/23/2017 as a pre-IPO investment from Tango Therapeutics, Inc., and payment for that acquisition was by wire. The filing also discloses a related sale in the past three months: Third Rock Ventures IV, L.P. sold 1,100,000 common shares on 08/19/2025 for gross proceeds of $7,712,760.00. The notice includes the filer’s standard representation that no undisclosed material adverse information is known.

Positive

• Clear compliance disclosure under Rule 144 with specific quantities, dates, and broker information
• Acquisition details provided (pre-IPO acquisition date and payment method), aiding transparency

Negative

• Insider/affiliate selling disclosed: 302,194 shares proposed and 1,100,000 shares sold recently, which could increase share supply
• No contextual company performance information is provided in the filing to explain the sales

Insights

Securities Analyst

TL;DR: Routine Form 144 reporting insider-related sales; sizes are disclosed and consistent with resale pursuant to Rule 144.

The filing provides clear, transactional detail: the proposed sale of 302,194 shares at an aggregate market value of $2.09 million and a recent related sale of 1.1 million shares generating $7.71 million. These are explicit, contemporaneous disclosures required under Rule 144 and enable market transparency regarding potential supply into the market. The filing specifies acquisition date and nature (pre-IPO), which helps confirm holding period eligibility. There is no financial performance data or commentary in the filing to imply operational change.

Corporate Governance Expert

TL;DR: The document is a compliance filing showing secondary sales; it raises routine governance disclosure points rather than operational concerns.

The Form 144 furnishes required seller, acquisition, and transaction details and includes the signature representation about undisclosed material information. The disclosure of a sizable sale by an affiliated investor (Third Rock Ventures IV, L.P.) within three days of the proposed sale may be relevant to stakeholders assessing insider liquidity and share availability, but the filing itself contains no allegations or governance actions beyond standard attestations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tango Therapeutics (TNGX) disclose in this Form 144?

The filing reports a proposed sale of 302,194 common shares via BTIG on 08/22/2025 with aggregate market value of $2,085,138.60 and a prior sale of 1,100,000 shares on 08/19/2025 for $7,712,760.00.

Who is the broker handling the proposed sale for TNGX shares?

The broker listed for the proposed sale is BTIG, LLC, 350 Bush Street, 9th Floor, San Francisco, CA 94104.

When were the securities that are being sold originally acquired?

The shares were acquired on 03/23/2017 as a pre-IPO investment from Tango Therapeutics, Inc., with payment by wire.

How many Tango Therapeutics shares are outstanding according to the filing?

The filing lists 111,260,247 shares outstanding.

Does this Form 144 state any undisclosed material information about Tango Therapeutics?

The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/22/2025 - 05:26 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001688327
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tango Therapeutics, Inc.
SEC File Number	001-39485
Address of Issuer	201 BROOKLINE AVENUE SUITE 901 BOSTON MASSACHUSETTS 02215
Phone	(857) 320-4900
Name of Person for Whose Account the Securities are To Be Sold	Third Rock Ventures IV, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	BTIG, LLC 350 Bush Street 9th Floor San Francisco CA 94104	302194	2085138.60	111260247	08/22/2025	NASDAQ GM

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/23/2017	Pre-IPO investment	Tango Therapeutics Inc			302194	03/23/2017	Wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Third Rock Ventures IV, L.P. 201 BROOKLINE AVENUE Suite 1401 BOSTON MA 02215	Common	08/19/2025	1100000	7712760.00

144: Remarks and Signature

Remarks
Date of Notice	08/22/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Kevin Gillis
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)